

Clinical Trial Protocol

Iranian Registry of Clinical Trials

11 Sep 2026

“Effect of Different Doses of Intrathecal Magnesium Sulfate (MgSO₄) as an Adjunct for the Prevention of Shivering in Patients Undergoing Spinal Anesthesia”

Protocol summary

Study aim

Determining the effect of different doses of intrathecal magnesium sulfate (MgSO₄) as an adjunct to prevent shivering in patients undergoing spinal anesthesia

Design

A single-center, four-arm, parallel-group, blinded, randomized controlled trial involving 172 participants.

Settings and conduct

The trial will be conducted at Bacha Khan Medical Complex, Swabi, Pakistan. Eligible patients undergoing elective surgery under spinal anesthesia will be randomly allocated to one of four groups. Participants and outcome assessors will be blinded to group allocation. The assigned intervention will be administered according to the study protocol. Standard perioperative monitoring and postoperative follow-up will be performed.

Participants/Inclusion and exclusion criteria

1. Inclusion criteria: Age 18-60 years Elective infraumbilical surgeries Hemodynamically stable patient. ASA physical status I-II valid. Written informed consent provided 2. Exclusion criteria: Known allergy/hypersensitivity to MgSO₄ Patients on Ca channel blockers or sedative medications Baseline hypothermia or fever Neurological or neuromuscular disorders Severe hepatic, renal, cardiac disease Patients with contraindications to spinal anesthesia, such as infection at the injection site and coagulopathy. Patients requiring conversion to general anesthesia Pregnant patients (exclude if not specifically studying cesarean cases)

Intervention groups

Group A will receive 25 mg intrathecal MgSO₄, Group B will receive 50 mg, and Group C will receive 75 mg as an adjunct to spinal anesthesia.

Main outcome variables

Incidence and severity of shivering Adverse effects: Hypotension, Bradycardia, Nausea/vomiting: Sedation level (Ramsay Sedation Scale) Core body temperature

Hemodynamic parameters: HR,BP Duration of motor block Duration of sensory block Onset of sensory block: patient satisfaction

General information

Reason for update

Acronym

DIMS (Dose of Intrathecal MgSo4)

IRCT registration information

IRCT registration number: **IRCT20260225068945N1**

Registration date: **2026-08-15, 1405/05/24**

Registration timing: **registered_while_recruiting**

Last update: **2026-08-15, 1405/05/24**

Update count: **0**

Registration date

2026-08-15, 1405/05/24

Registrant information

Name

Muhammad Farman

Name of organization / entity

Khyber Medical University, Peshawar

Country

Pakistan

Phone

+92 311 9148070

Email address

muhammadfarman782@gmail.com

Recruitment status

recruiting

Funding source

Expected recruitment start date

2026-06-25, 1405/04/04

Expected recruitment end date

2026-11-05, 1405/08/14

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

"Effect of Different Doses of Intrathecal Magnesium Sulfate (MgSO₄) as an Adjunct for the Prevention of Shivering in Patients Undergoing Spinal Anesthesia"

Public title

"Effect of Different Doses of Intrathecal Magnesium Sulfate (MgSO₄) as an Adjunct for the Prevention of Shivering in Patients Undergoing Spinal Anesthesia"

Purpose

Prevention

Inclusion/Exclusion criteria**Inclusion criteria:**

Age 18-60 years Elective infraumbilical surgeries ASA physical status I-II valid Hemodynamically stable patient Written informed consent provided

Exclusion criteria:

Known allergy/hypersensitivity to MgSO₄ Patients on Ca channel blockers or sedative medications Baseline hypothermia or fever Neurological or neuromuscular disorders Severe hepatic, renal, cardiac disease Patients with contraindications to spinal anesthesia, such as infection at the injection site and coagulopathy Patients requiring conversion to general anesthesia Pregnant patients (exclude if not specifically studying cesarean cases)

AgeFrom **18 years** old to **60 years** old**Gender**

Both

Phase

2

Groups that have been masked

- Care provider

Sample sizeTarget sample size: **172****Randomization (investigator's opinion)**

Randomized

Randomization description

All participants will be given clear information about the study through the clinical trial information sheet. Written consent will be obtained from those who meet the eligibility criteria and agree to participate. Eligible patients will then be randomly assigned to one of three groups using (25 mg, 50 mg, 75 mg) Magnesium Sulfate. Patients in the intervention group will receive spinal anesthesia with 0.5% hyperbaric bupivacaine along with 25mg, 50mg, 75mg of intrathecal magnesium sulfate diluted in normal saline. Patients in the control group will receive only spinal anesthesia with 0.5% hyperbaric bupivacaine intrathecally. We will record how often shivering occurs during and after surgery and grade its severity using a standard shivering scale. All patients will be closely monitored for blood pressure, heart rate, and

any side effects related to intrathecal magnesium sulfate during and after the procedure. • The study drug will be prepared according to group allocation: □ Group A: 25 mg Mg SO₄ □ Group B: 50 mg Mg SO₄ □ Group C: 75 mg Mg SO₄ • Spinal anesthesia will be administered at L3-L4 or L4-L5 using standard technique with 0.5% hyperbaric bupivacaine plus study drug. • Patients will remain unaware of group allocation (single-blind). A trained independent observer, blinded to group allocation, will record all intraoperative observations. • Standard monitoring (ECG, NIBP, SpO₂) will be applied. Parameters will be recorded at predefined intervals (0, 5, 10, 15, 30, 45, 60 minutes): □ Heart rate □ Blood pressure □ Core temperature □ Shivering score (Wrench scale) • Primary outcome: Incidence and severity of shivering will be assessed using the Wrench shivering scale (0-4). • Secondary Outcomes will be recorded: □ Onset and duration of sensory block □ Duration of motor block □ Sedation level (Ramsay scale) □ Adverse effects (hypotension, bradycardia, nausea, vomiting) • Management of Adverse Events: □ Hypotension will be treated with IV fluids and vasopressors □ Bradycardia will be treated with atropine. □ The antidote for magnesium sulfate is Calcium gluconate. □ All adverse events will be recorded in the pro forma • Data will be recorded on a structured questionnaire. Each patient will be assigned a unique ID number. Data will be entered into SPSS software for analysis, and confidentiality will be maintained throughout.

Blinding (investigator's opinion)

Single blinded

Blinding description

Patients in the intervention group will receive spinal anesthesia with 0.5% hyperbaric bupivacaine along with 25mg, 50mg, 75mg of intrathecal magnesium sulfate diluted in normal saline. Patients in the control group will receive only spinal anesthesia with 0.5% hyperbaric bupivacaine intrathecally.

Placebo

Used

Assignment

Parallel

Other design features

N/A

Secondary Ids

empty

Ethics committees1**Ethics committee****Name of ethics committee**

Ethics Committee of Khyber Medical University

Street address

Phase-V, Hayatabad Peshawar.

City

Peshawar

Postal code

25100

Approval date

2026-06-29, 1405/04/08

Ethics committee reference number

No: KMU/Dean/AHS-26/2305

Health conditions studied**1****Description of health condition studied**

Prevention of shivering in patients undergoing spinal anesthesia

ICD-10 code

O89.5

ICD-10 code description

Other complications of spinal and epidural anesthesia during the puerperium

Primary outcomes**1****Description**

"Incidence of Postoperative Shivering." The shivering that occurs after spinal anesthesia, it will be measured using the wrench shivering scale intraoperatively and 60 mins postoperatively

Timepoint

Intraoperatively and 60 mins postoperatively

Method of measurement

Temperature and physical examination

Secondary outcomes**1****Description**

Onset of sensory block (mins); Time from intrathecal injection to T10 level sensory block

Timepoint

2-6 hours post spinal

Method of measurement

Bilateral sensation to cold/pinprick

2**Description**

Duration of Sensory Block (mins); Time from maximum sensory block till regression to S1 level

Timepoint

Every 15 minutes after maximum block till S1 level

Method of measurement

Regression of sensory block using cold/pinprick

3**Description**

Duration of motor block (mins); Time from maximum motor block till recovery of bromage score to "0"

Timepoint

Every 15 minutes after spinal anesthesia till motor recovery

Method of measurement

By using modified Bromage scale till Bromage=0

4**Description**

Heart rate changes

Timepoint

Baseline, every 5 min intraoperatively, in recovery

Method of measurement

Measured using continuous ECG monitor

5**Description**

Blood pressure changes

Timepoint

Baseline, every 5 min intraoperatively, in recovery

Method of measurement

Noninvasive, using automated monitor

6**Description**

Incidence of Hypotension,, Blood Pressure more than 20% decrease from baseline

Timepoint

from intrathecal injection till end of surgery

Method of measurement

Blood Pressure more than 20% decrease from baseline

7**Description**

Incidence of bradycardia

Timepoint

From intrathecal injection till end of surgery

Method of measurement

Continuous ECG monitoring, less than 50 beats/min is considered as bradycardia

8**Description**

Postoperative pain intensity

Timepoint

At recovery, 2, 4, 6, 12 and 24 hours postoperatively

Method of measurement

VAS/NRS (0-10)

9**Description**

Sedation level

Timepoint

At recovery, 30 min, 1, 2, 4 and 6 hours postoperatively

Method of measurement

Ramsay Sedation Scale (RSS)

10**Description**

Incidence of adverse effects

Timepoint

Intraoperatively and up to 24 hours postoperatively
Method of measurement
Clinical assessment and documentation of nausea, vomiting, pruritus, respiratory depression and other adverse events

11

Description

Patient satisfaction

Timepoint

At 24 hours postoperatively

Method of measurement

Structured patient satisfaction assessment using a predefined satisfaction scale

Intervention groups

1

Description

Control group: Normal Saline as an adjunct with Bupivacaine SP

Category

Placebo

2

Description

Intervention group 1: 25 mg MgSO₄ as an adjunct with Bupivacaine SP

Category

Treatment - Drugs

3

Description

Intervention group 2: 50 mg MgSO₄ as an adjunct with Bupivacaine SP

Category

Treatment - Drugs

4

Description

Intervention group 3: 75 mg MgSO₄ as an adjunct with Bupivacaine SP

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Gulrang International Hospital

Full name of responsible person

Dr Arshad Ali

Street address

N-45, Dheri Alladand, Malakand.

City

Malakand

Postal code

23020

Phone

+92 311 9148070

Email

hr@gulranghospital.org

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Khyber Medical University, Pakistan & Green International University, Pakistan

Full name of responsible person

Mr. Muhammad Farman

Street address

Moh Karigaraan, Pindi ROad Togh Bala Teh/Distt Kohat

City

Kohat

Postal code

26010

Phone

+92 311 9148070

Fax

Email

mfarman.ihsswabi@kmu.edu.pk

Web page address

<https://kmu.edu.pk/>

Grant name

Research Reimbursement

Grant code / Reference number

Not issued yet, applied for it

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Khyber Medical University, Pakistan & Green International University, Pakistan

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Khyber Medical University, Peshawar

Full name of responsible person

Muhammad Farman

Position

Lecturer
Latest degree
Master
Other areas of specialty/work
Public Health
Street address
Phase 5 Hayatabad
City
Peshawar
Province
Khyber Pakhtunkhwa
Postal code
25100
Phone
+92 311 9148070
Email
muhammadfarman782@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Khyber Medical University
Full name of responsible person
Muhammad Farman
Position
Lecturer
Latest degree
Master
Other areas of specialty/work
Anesthesiology
Street address
Mohallah Karigaran Pindi Road Togh Bala Tehsil
District Kohat
City
Kohat
Province
Khyber Pakhtunkhwa
Postal code
26010
Phone
+92 311 9148070
Email
muhammadfarman782@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
Khyber Medical University
Full name of responsible person
Muhammad Farman
Position

Lecturer
Latest degree
Master
Other areas of specialty/work
Anesthesiology
Street address
Mohallah Karigaran Pindi Road Togh Bala Tehsil
District Kohat
City
Kohat
Province
Khyber Pakhtunkhwa
Postal code
26010
Phone
+92 311 9148070
Fax
Email
muhammadfarman782@gmail.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Effect of different doses of intrathecal MgSO₄ as an adjunct for the prevention of shivering in patients undergoing spinal anesthesia

When the data will become available and for how long

After publication for 6 months

To whom data/document is available

Principal Investigator

Under which criteria data/document could be used

N/A

From where data/document is obtainable

via email muhammadfarman782@gmail.com

What processes are involved for a request to access data/document

via email muhammadfarman782@gmail.com

Comments